Search Results - "Belau, Antje Kristina"

Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ) by Chekerov, Radoslav, Arndt, Tjadina, Pietzner, Klaus, Canzler, Ulrich, Wimberger, Pauline, Strauß, Hans-Georg, Mahner, Sven, Woelber, Linn, de Gregorio, Nikolaus, Stocker, Gertraud, von Abel, Ekkehard, Neunhoeffer, Tanja, Belau, Antje Kristina, Mustea, Alexander, Yalinkaya, Isil, Braicu, Elena Ioana, Richter, Rolf, Sehouli, Jalid

“…Purpose Pazopanib has promising antiangiogenetic activity in solid cancers. The investigator-initiated phase I/II trial evaluated the combination of Topotecan…”
Get full text

Topotecan (T) + Pazopanib (P) in platinum-resistant or intermediate-sensitive ovarian cancer: a phase I/II single-arm multicentre trial of the North-Eastern German Society of Gynaecologic Oncology: TOPAZ by Chekerov, Radoslav, Canzler, Ulrich, Strauss, Hans-Georg, Müller, Volkmar, de Gregorio, Nikolaus, Hacker, Ulrich, Neunhoeffer, Tanja, Richter, Rolf, Braicu, Elena Ioana, Inci, Guelhan, Pietzner, Klaus, Yalcinkaya, Isil, Belau, Antje Kristina, von Abel, Ekkehard, Wimberger, Pauline, Sehouli, Jalid

“…Abstract only…”
Get full text

AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer—Overall survival (OS) results by Vergote, Ignace, Hanker, Lars Christian, Floquet, Anne, Rau, Joern, Kim, Jae-Weon, Ortega Izquierdo, Eugenia, Friedlander, Michael, Pignata, Sandro, Fujiwara, Keiichi, Colombo, Nicoletta, Mirza, Mansoor Raza, Monk, Bradley J., Mörtl, Manfred, Calvert, Paula, Herzog, Thomas J., Jackisch, Christian, Meunier, Jérome, Lee, Jung-Yun, Belau, Antje Kristina, Du Bois, Andreas

“…Abstract only…”
Get full text

Prediction of post-operative residual disease in advanced-stage ovarian cancer (AOC) using whole transcriptome expression: An exploratory analysis of the AGO-OVAR 11 (ICON7) trial by Heitz, Florian, Kommoss, Stefan, Winterhoff, Boris J. N., Aliferis, Constantin, Burges, Alexander, Wang, Chen, Canzler, Ulrich, Wang, Jinhua, Belau, Antje Kristina, Hanker, Lars Christian, Ma, Sisi, Hilpert, Felix, Sehouli, Jalid, Tourani, Roshan, Kimmig, Rainer, Kurzeder, Christian, Schmalfeldt, Barbara, Dowdy, Sean Christopher, Du Bois, Andreas, Pfisterer, Jacobus

“…Abstract only…”
Get full text

LION-PAW: Lymphadenectomy in ovarian neoplasm-pleasure ability of women—Prospective substudy of the randomized multicenter LION study by Hasenburg, Annette, Sehouli, Jalid, Lampe, Boern, Reuss, Alexander, Schmalfeldt, Barbara, Belau, Antje Kristina, Bossart, Michaela, Mahner, Sven, Hillemanns, Peter, Petry, Karl-Ulrich, Du Bois, Andreas, Herwig, Uwe, Hilpert, Felix, Gropp-Meier, Martina, Hanf, Volker, Janni, Wolfgang, Greimel, Elfriede, Wagner, Uwe A. G., Harter, Philipp

“…Abstract only…”
Get full text

Non-pegylated liposomal doxorubicin for patients with recurrent ovarian cancer: A multicentric phase II trial by Brucker, Janina, Mayer, Christine, Gebauer, Gerhard, Mallmann, Peter, Belau, Antje Kristina, Schneeweiss, Andreas, Sohn, Christof, Eichbaum, Michael

“…Patients with non-platinum-sensitive recurrent ovarian cancer have a poor prognosis. Non-pegylated liposomal doxorubicin (Myocet®) is a promising drug that may…”
Get full text